Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia

Australasian Journal of Dermatology

Volumn 52, Issue 1, 2011, Pages 59-61

  Milne, Olivia ^a   Cutts, Briony ^a   McLean, Catriona ^a   Gin, Douglas ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Acral erythema; Acral erythrodysesthesia; Adverse reaction; Cutaneous reaction; Drug reaction; Hand foot syndrome; Human keratinocyte growth factor; Palifermin; Palmar plantar syndrome; Toxic erythema of palms and soles

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; OPIATE; PALIFERMIN; VANCOMYCIN;

ACRAL ERYTHRODYSESTHESIA; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARM; ARTICLE; BACK; BLISTER; BURNING SENSATION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELL VACUOLE; DESQUAMATION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG MECHANISM; DYSESTHESIA; DYSKERATOSIS; EOSINOPHIL; EPIDERMOLYSIS; FINGER; HAND ERYTHEMA; HAND FOOT SYNDROME; HEALING; HEAT SENSATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; HYPERPLASIA; KERATINOCYTE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NECK; ORAL MUCOSAL DISEASE; ORAL MUCOSITIS; PAIN; PALLOR; PARENTERAL NUTRITION; PUNCH BIOPSY; RETREATMENT; SCAR FORMATION; SHOULDER; SIDE EFFECT; SKIN BIOPSY; SKIN BLOOD VESSEL; SKIN MANIFESTATION; SKIN NECROSIS; TREATMENT DURATION;

FIBROBLAST GROWTH FACTOR 7; HUMANS; LEUKEMIA, MYELOID, ACUTE; PARESTHESIA; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 79952054132     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2010.00682.x     Document Type: Article

References (15)

1. Keefe DM, Shubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-31. (Pubitemid 46335677)
2. Rubenstein EB, Peterson DE, Shubert MM et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100: 2026-46. (Pubitemid 38525884)
3. Bradstock KF, Matthews JP, Lowenthal RM et al. A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-8. (Pubitemid 40070725)
4. McDonnell AM, Lenz KL. Palifermin: role in the prevention of chemotherapy and radiation-induced mucositis. Ann. Pharmacother. 2007; 41: 86-93.
5. National Cancer Institute. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3.0. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. (Accessed 10 Apr 2009.)
6. Hueso L, Sanmartin O, Nagore E et al. Chemotherapy-induced acral erythema: a clinical and histopathological study of 44 cases. Actas Dermosifiliogr. 2008; 99: 281-90. (Pubitemid 351729646)
7. Janusch M, Fischer M, Marsch WCH et al. The hand-foot syndrome: a frequent secondary manifestation in antineoplastic chemotherapy. Eur. J. Dermatol. 2006; 16: 494-5.
8. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for haematologic cancers. N. Engl. J. Med. 2004; 351: 2590-8. (Pubitemid 39628580)
9. Diaz Ley B, Guhl G, Eguren Michelena C et al. Flexural cutaneous eruption due to palifermin. Br. J. Haematol. 2007; 140: 464-5.
10. Sibelt LAG, Aboosy N, van der Velden WJFM et al. Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases. Br. J. Dermatol. 2008; 159: 1200-3.
11. Lane SW, Manoharan S, Mollee PN. Palifermin-induced acanthosis nigricans. Intern. Med. J. 2007; 37: 417-18. (Pubitemid 47029881)
12. Keijzer A, Huijgens PC, van de Loosdrecht AA. Palifermin and palmar-plantar erythrodysesthesia. Br. J. Haematol. 2007; 136: 856-7.
13. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J. Am. Acad. Dermatol. 1999; 40: 367.
14. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr. Opin. Oncol. 2002; 14: 212-16. (Pubitemid 34235056)
15. Milano G, Etienne-Grimaldi MC, Mari M et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br. J. Clin. Pharmacol. 2008; 66: 88-95. (Pubitemid 351822156)